QQQ   309.36 (-0.13%)
AAPL   159.10 (+0.11%)
MSFT   278.95 (+0.46%)
META   205.70 (+0.70%)
GOOGL   104.97 (-0.60%)
AMZN   97.63 (-1.09%)
TSLA   189.64 (-1.34%)
NVDA   266.77 (-1.89%)
NIO   8.99 (-3.02%)
BABA   86.58 (+0.07%)
AMD   97.90 (-2.37%)
T   18.50 (+0.22%)
F   11.44 (+0.18%)
MU   61.11 (-0.37%)
CGC   1.92 (+0.26%)
GE   92.32 (+0.80%)
DIS   93.78 (-2.14%)
AMC   4.45 (-0.45%)
PFE   40.24 (+0.15%)
PYPL   73.56 (+1.38%)
NFLX   328.30 (+2.48%)
QQQ   309.36 (-0.13%)
AAPL   159.10 (+0.11%)
MSFT   278.95 (+0.46%)
META   205.70 (+0.70%)
GOOGL   104.97 (-0.60%)
AMZN   97.63 (-1.09%)
TSLA   189.64 (-1.34%)
NVDA   266.77 (-1.89%)
NIO   8.99 (-3.02%)
BABA   86.58 (+0.07%)
AMD   97.90 (-2.37%)
T   18.50 (+0.22%)
F   11.44 (+0.18%)
MU   61.11 (-0.37%)
CGC   1.92 (+0.26%)
GE   92.32 (+0.80%)
DIS   93.78 (-2.14%)
AMC   4.45 (-0.45%)
PFE   40.24 (+0.15%)
PYPL   73.56 (+1.38%)
NFLX   328.30 (+2.48%)
QQQ   309.36 (-0.13%)
AAPL   159.10 (+0.11%)
MSFT   278.95 (+0.46%)
META   205.70 (+0.70%)
GOOGL   104.97 (-0.60%)
AMZN   97.63 (-1.09%)
TSLA   189.64 (-1.34%)
NVDA   266.77 (-1.89%)
NIO   8.99 (-3.02%)
BABA   86.58 (+0.07%)
AMD   97.90 (-2.37%)
T   18.50 (+0.22%)
F   11.44 (+0.18%)
MU   61.11 (-0.37%)
CGC   1.92 (+0.26%)
GE   92.32 (+0.80%)
DIS   93.78 (-2.14%)
AMC   4.45 (-0.45%)
PFE   40.24 (+0.15%)
PYPL   73.56 (+1.38%)
NFLX   328.30 (+2.48%)
QQQ   309.36 (-0.13%)
AAPL   159.10 (+0.11%)
MSFT   278.95 (+0.46%)
META   205.70 (+0.70%)
GOOGL   104.97 (-0.60%)
AMZN   97.63 (-1.09%)
TSLA   189.64 (-1.34%)
NVDA   266.77 (-1.89%)
NIO   8.99 (-3.02%)
BABA   86.58 (+0.07%)
AMD   97.90 (-2.37%)
T   18.50 (+0.22%)
F   11.44 (+0.18%)
MU   61.11 (-0.37%)
CGC   1.92 (+0.26%)
GE   92.32 (+0.80%)
DIS   93.78 (-2.14%)
AMC   4.45 (-0.45%)
PFE   40.24 (+0.15%)
PYPL   73.56 (+1.38%)
NFLX   328.30 (+2.48%)
NASDAQ:PHAR

Pharming Group - PHAR Stock Forecast, Price & News

$10.71
-0.56 (-4.97%)
(As of 03/24/2023 11:50 AM ET)
Add
Compare
Today's Range
$10.03
▼
$11.11
50-Day Range
$10.24
▼
$14.78
52-Week Range
$6.10
▼
$15.00
Volume
14,268 shs
Average Volume
6,858 shs
Market Capitalization
$703.00 million
P/E Ratio
56.37
Dividend Yield
N/A
Price Target
$37.00

Pharming Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
254.1% Upside
$37.00 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.36mentions of Pharming Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

329th out of 989 stocks

Pharmaceutical Preparations Industry

145th out of 480 stocks

See Top Rated MarketRank™ Stocks Here

PHAR stock logo

About Pharming Group (NASDAQ:PHAR) Stock

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHAR Stock News Headlines

March 18, 2023 | finance.yahoo.com
Pharming Group Full Year 2022 Earnings: EPS: US$0.021 (vs US$0.025 in FY 2021)
March 17, 2023 | americanbankingnews.com
Pharming Group (NASDAQ:PHAR) Shares Gap Down to $12.65
March 24, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 16, 2023 | marketwatch.com
2023 Lactoferrin and Lactoperoxidase Market Size Forecast 2029: Global Leaders' Sales and Profit Analysis for Business Growth
March 15, 2023 | marketwatch.com
Hereditary Angioedema Therapeutic Market Application, Product, Sales and Forecast 2023-2028
March 14, 2023 | finance.yahoo.com
Why Earnings Season Could Be Great for Pharming Group (PHAR)
March 13, 2023 | marketwatch.com
Pharming Expects to Have Access to $26 Mln It Has on Deposit at SVB US
March 13, 2023 | finance.yahoo.com
Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcement
March 24, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 12, 2023 | finanznachrichten.de
Pharming Group N.V.: Pharming Group issues statement regarding the events surrounding Silicon Valley Bank
March 12, 2023 | finance.yahoo.com
Pharming Group issues statement regarding the events surrounding Silicon Valley Bank
March 12, 2023 | finance.yahoo.com
Dutch biotech Pharming says it held $45 mln in collapsed SVB
February 17, 2023 | marketwatch.com
Ischemia Reperfusion Injury Therapeutics Market Insights-Industry changing aspects, New Technologies and Forecast to 2028
February 16, 2023 | msn.com
Why Boston Beer Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 16, 2023 | finanznachrichten.de
Pharming Group N.V.: Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
February 16, 2023 | finance.yahoo.com
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
February 13, 2023 | marketwatch.com
Recombinant Proteins for Clinical Use Market Will Touch New Level in Upcoming Year
January 19, 2023 | marketwatch.com
Hereditary Angioedema Treatment Market 2023 : Company Profile Analysis, Industry Segmentation, Opportunity Assessment and Forecast by 2028
December 15, 2022 | markets.businessinsider.com
Pharming Reports Positive Interim Data From Study Of Leniolisib In Rare Primary Immunodeficiency
December 7, 2022 | seekingalpha.com
Pharming reports publishing of phase 3 data of rare immunodeficiency disorder drug
December 7, 2022 | finanznachrichten.de
Pharming Group NV: Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
December 7, 2022 | markets.businessinsider.com
Pharming : Positive Data From Phase 3 Study Of Leniolisib In Rare Primary Immunodeficiency Published
December 7, 2022 | marketwatch.com
Pharming Group's Leniolisib Phase 3 Study Shows Positive Data
December 1, 2022 | finance.yahoo.com
Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?
November 24, 2022 | finanznachrichten.de
Pharming Group N.V.: Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting
November 3, 2022 | finanznachrichten.de
Pharming Group N.V.: Pharming to present at Stifel Healthcare Conference
November 3, 2022 | finance.yahoo.com
Pharming to present at Jefferies Healthcare Conference
See More Headlines
Receive PHAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter.

PHAR Company Calendar

Today
3/24/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHAR
CUSIP
N/A
CIK
1828316
Web
www.pharming.com
Phone
31-71-524-7400
Fax
N/A
Employees
262
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+254.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.19
Trailing P/E Ratio
55.00
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$13.67 million
Net Margins
6.65%
Pretax Margin
7.29%
Return on Equity
1.08%
Return on Assets
0.54%

Debt

Debt-to-Equity Ratio
0.64
Current Ratio
4.65
Quick Ratio
3.94

Sales & Book Value

Annual Sales
$205.62 million
Price / Sales
3.34
Cash Flow
$0.23 per share
Price / Cash Flow
44.76
Book Value
$3.12 per share
Price / Book
3.35

Miscellaneous

Outstanding Shares
65,640,000
Free Float
64,276,000
Market Cap
$685.94 million
Optionable
Not Optionable
Beta
0.26

Key Executives

  • Dr. Sijmen de Vries M.B.A. (Age 63)
    M.D., MBA, Pres, CEO & Exec. Director
    Comp: $1.2M
  • Dr. Bruno M. L. Giannetti (Age 70)
    Consultant
  • Mr. Jeroen Wakkerman (Age 53)
    Chief Financial Officer
  • Ms. Mireille Sanders M.Sc. (Age 54)
    Chief Operations Officer
  • Susanne Embleton
    Investor Relations Mang.
  • Mr. Ruud Van Outersterp (Age 58)
    Chief Ethics & Compliance Officer
  • Mr. Anurag Relan (Age 50)
    Chief Medical Officer
  • Mr. Stephen Toor (Age 51)
    Chief Commercial Officer & GM of Americas

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













PHAR Stock - Frequently Asked Questions

Should I buy or sell Pharming Group stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pharming Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHAR shares.
View PHAR analyst ratings or view top-rated stocks.

What is Pharming Group's stock price forecast for 2023?

1 equities research analysts have issued twelve-month price targets for Pharming Group's stock. Their PHAR share price forecasts range from $37.00 to $37.00. On average, they predict the company's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 254.1% from the stock's current price.
View analysts price targets for PHAR or view top-rated stocks among Wall Street analysts.

How have PHAR shares performed in 2023?

Pharming Group's stock was trading at $11.03 at the beginning of the year. Since then, PHAR stock has decreased by 5.3% and is now trading at $10.45.
View the best growth stocks for 2023 here.

Are investors shorting Pharming Group?

Pharming Group saw a drop in short interest in February. As of February 28th, there was short interest totaling 2,000 shares, a drop of 33.3% from the February 13th total of 3,000 shares. Based on an average daily volume of 4,300 shares, the days-to-cover ratio is presently 0.5 days.
View Pharming Group's Short Interest.

When is Pharming Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our PHAR earnings forecast.

What is Pharming Group's stock symbol?

Pharming Group trades on the NASDAQ under the ticker symbol "PHAR."

Who are Pharming Group's major shareholders?

Pharming Group's stock is owned by a number of retail and institutional investors. Top institutional investors include Cowen Prime Advisors LLC (0.03%).

How do I buy shares of Pharming Group?

Shares of PHAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharming Group's stock price today?

One share of PHAR stock can currently be purchased for approximately $10.45.

How much money does Pharming Group make?

Pharming Group (NASDAQ:PHAR) has a market capitalization of $685.94 million and generates $205.62 million in revenue each year. The company earns $13.67 million in net income (profit) each year or $0.19 on an earnings per share basis.

How many employees does Pharming Group have?

The company employs 262 workers across the globe.

How can I contact Pharming Group?

Pharming Group's mailing address is DARWINWEG 24, LEIDEN P7, 2333 CR. The official website for the company is www.pharming.com. The company can be reached via phone at 31-71-524-7400 or via email at investor@pharming.com.

This page (NASDAQ:PHAR) was last updated on 3/24/2023 by MarketBeat.com Staff